Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 02, 2024	Oct. 28, 2023	Nov. 02, 2024	Oct. 28, 2023	Feb. 03, 2024
Operating activities
Net income			$ 9,298	$ 30,114
Add (deduct) items not affecting operating cash flows:
Depreciation and amortization			3,066	3,703
Allowance for doubtful accounts			(32)	(17)
Gain on sale of intangible assets				(32,808)
Gain on sale of subsidiary			(7,634)
Loss on disposal of property and equipment			40	230
Amortization of deferred financing costs			239	673
Deferred income taxes			(1,346)	(5,905)
Share-based compensation expense	$ 307	$ 342	557	1,155
Capitalized PIK Interest due to loan with related party			3,455	2,875
Loss on debt extinguishment				3,136
Equity in net income of equity method investment, net of distributions			2,593	(475)
Changes in assets and liabilities:
Receivables, net			(8,742)	(7,584)
Inventories			(4,992)	20,441
Prepaid expenses and other current assets			(2,072)	(366)
Accounts payable and accrued expenses			6,334	(23,921)
Other assets and liabilities			(1,397)	(4,372)
Net cash used in operating activities			(633)	(13,121)
Investing activities
Payments for capital expenditures			(2,725)	(920)
Transaction costs related to equity method investment				(525)
Proceeds from Sale of Intangible Assets				77,525
Net cash (used in) provided by investing activities			(2,725)	76,080
Financing activities
Proceeds from borrowings under the Revolving Credit Facilities			164,300	219,266
Repayment of borrowings under the Revolving Credit Facilities			(161,170)	(248,387)
Repayment of borrowings under the Term Loan Facilities				(29,378)
Tax withholdings related to restricted stock vesting			(56)	(141)
Proceeds from stock option exercises, restricted stock vesting, and issuance of common stock under employee stock purchase plan			21	38
Financing fees			(8)	(3,012)
Net cash provided by (used in) financing activities			3,087	(61,614)
(Decrease) increase in cash, cash equivalents, and restricted cash			(271)	1,345
Effect of exchange rate changes on cash, cash equivalents, and restricted cash			3	(7)
Cash, cash equivalents, and restricted cash, beginning of period			1,219	1,116	$ 1,116
Cash, cash equivalents, and restricted cash, end of period	951	2,454	951	2,454	1,219
Less: restricted cash at end of period	59	1,237	59	1,237
Cash and cash equivalents per balance sheet at end of period	$ 892	$ 1,217	892	1,217	$ 357
Supplemental Disclosures of Cash Flow Information
Cash payments for interest			1,418	5,807
Cash payments for income taxes, net of refunds			245	437
Supplemental Disclosures of Non-Cash Investing and Financing Activities
Non-cash equity method investment				25,500
Capital expenditures in accounts payable and accrued liabilities			$ 423	102
Deferred financing fees in accrued liabilities				$ 323